Collegium Pharmaceutical Hits Record Quarterly Revenue, Boosts Guidance and Authorizes Buyback
Third Avenue Small-Cap Value Fund returned 4.62% in Q4 2025 versus a 3.13% index gain, highlighting Collegium Pharmaceutical’s record quarterly revenue, upgraded operating income guidance and new share repurchase authorization as primary drivers. Collegium has a $1.183 billion market cap and shares are up 24.27% over the past year.
1. Fund Outperformance and Contribution
Third Avenue Small-Cap Value Fund delivered a 4.62% return in Q4 2025, outperforming the MSCI USA Small-Cap Value Index’s 3.13% gain. The fund letter cited Collegium Pharmaceutical’s record quarterly revenue, upgraded operating income guidance and new share repurchase authorization as leading performance drivers.
2. Record Quarterly Results
Collegium Pharmaceutical generated its highest quarterly revenue to date, driven by robust sales of its pain management portfolio. This record performance contributed materially to the fund’s outperformance during the period.
3. Guidance Upgrade and Buyback Authorization
Management raised full-year operating income guidance following the strong revenue results and approved a new share repurchase program. The authorization underscores the company’s commitment to returning capital and enhancing shareholder value.
4. Share Performance and Ownership Trends
Collegium shares have climbed 24.27% over the past 52 weeks despite a 20.28% decline over the last month, reflecting volatility around earnings. Market capitalization stands at $1.183 billion, and hedge fund ownership increased from 27 to 34 portfolios in Q4.